{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:17:21Z","timestamp":1790605041600,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.rdc.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:22:58Z","timestamp":1719397378000},"page":"423-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Connective Tissue Disease Associated Interstitial Lung Disease"],"prefix":"10.1016","volume":"50","author":[{"given":"Scott M.","family":"Matson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kristen","family":"Demoruelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2024.03.001_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.03.001_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.03.001_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.rmed.2013.05.002","article-title":"Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"107","author":"Solomon","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib7","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2024.03.001_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.03.001_bib9","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.rdc.2024.03.001_bib10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/art.1780261015","article-title":"Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis","volume":"26","author":"Cannon","year":"1983","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2024.03.001_bib13","doi-asserted-by":"crossref","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib14","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s10067-022-06245-5","article-title":"Can we finally exonerate methotrexate as a factor in causing or exacerbating fibrotic interstitial lung disease in patients with rheumatoid arthritis?","volume":"41","author":"Mehta","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thx.52.4.377","article-title":"Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis","volume":"52","author":"Schnabel","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.rdc.2024.03.001_bib16","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.rdc.2024.03.001_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/03009740601153774","article-title":"Rheumatoid arthritis treatment and the risk of severe interstitial lung disease","volume":"36","author":"Wolfe","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib18","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.rdc.2024.03.001_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","article-title":"Biological treatments and connective tissue disease associated interstitial lung disease","volume":"17","author":"Panopoulos","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib20","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s10067-021-06040-8","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis","volume":"41","author":"Rojas-Serrano","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib23","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib25","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2024.03.001_bib26","doi-asserted-by":"crossref","first-page":"2002533","DOI":"10.1183\/13993003.02533-2020","article-title":"Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Matson","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41379-022-01053-3","article-title":"Usual interstitial pneumonia (UIP): a clinically significant pathologic diagnosis","volume":"35","author":"Mukhopadhyay","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.rdc.2024.03.001_bib28","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib29","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib30","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2024.03.001_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib32","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1183\/09031936.00073012","article-title":"The pathogenesis of pulmonary fibrosis: a moving target","volume":"41","author":"Wuyts","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1513\/pats.200710-159DR","article-title":"Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis","volume":"5","author":"Laurent","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rdc.2024.03.001_bib35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib36","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/annrheumdis-2021-220698","article-title":"Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers","volume":"80","author":"Palomaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.03.001_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","article-title":"A\u00a0common MUC5B promoter polymorphism and pulmonary fibrosis","volume":"364","author":"Seibold","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib38","doi-asserted-by":"crossref","first-page":"684699","DOI":"10.3389\/fimmu.2021.684699","article-title":"Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations","volume":"12","author":"Shao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2024.03.001_bib39","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib40","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"British Rheumatoid Interstitial Lung N. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2024.03.001_bib41","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib42","doi-asserted-by":"crossref","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2024.03.001_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib45","doi-asserted-by":"crossref","first-page":"152088","DOI":"10.1016\/j.semarthrit.2022.152088","article-title":"The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies: a systematic review","volume":"57","author":"Teel","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.03.001_bib46","doi-asserted-by":"crossref","first-page":"e98794","DOI":"10.1371\/journal.pone.0098794","article-title":"Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease","volume":"9","author":"Giles","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2024.03.001_bib47","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.rdc.2024.03.001_bib48","doi-asserted-by":"crossref","first-page":"785275","DOI":"10.3389\/fimmu.2021.785275","article-title":"N-Formyl methionine peptide-mediated neutrophil activation in systemic sclerosis","volume":"12","author":"Kuley","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2024.03.001_bib49","doi-asserted-by":"crossref","first-page":"178ra140","DOI":"10.1126\/scitranslmed.3005580","article-title":"NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis","volume":"5","author":"Khandpur","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.rdc.2024.03.001_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.rdc.2024.03.001_bib51","doi-asserted-by":"crossref","first-page":"e32366","DOI":"10.1371\/journal.pone.0032366","article-title":"Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones","volume":"7","author":"Saffarzadeh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2024.03.001_bib52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.4359","article-title":"Neutrophil extracellular traps promote differentiation and function of fibroblasts","volume":"233","author":"Chrysanthopoulou","year":"2014","journal-title":"J\u00a0Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2024.03.001_bib53","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/jcmm.14858","article-title":"Neutrophil extracellular traps activate lung fibroblast to induce polymyositis-related interstitial lung diseases via TLR9-miR-7-Smad2 pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib54","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/annrheumdis-2013-204837","article-title":"Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2","volume":"74","author":"Carmona-Rivera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.03.001_bib55","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1183\/09031936.00127011","article-title":"A\u00a0neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice","volume":"40","author":"Takemasa","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.41948","article-title":"Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti-Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis","volume":"74","author":"Okamoto","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1378\/chest.07-1948","article-title":"Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis","volume":"133","author":"Kinder","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rdc.2024.03.001_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.03.001_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.rdc.2024.03.001_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1164\/rccm.202109-2087LE","article-title":"Prospective Identification of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Cohort is Associated with the MUC5B Promoter Variant","volume":"205","author":"Matson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.rdc.2024.03.001_bib61","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A\u00a0risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2024.03.001_bib62","doi-asserted-by":"crossref","first-page":"1602314","DOI":"10.1183\/13993003.02314-2016","article-title":"Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis","volume":"49","author":"Juge","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib63","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard.62.8.722","article-title":"Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years","volume":"62","author":"Turesson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2024.03.001_bib64","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib65","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2024.03.001_bib66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.reuma.2019.05.004","article-title":"Subclinical interstitial lung disease in patients with systemic sclerosis. A pilot study on the role of ultrasound","volume":"17","author":"Reyes-Long","year":"2021","journal-title":"Reumatol Cl\u00ednica"},{"key":"10.1016\/j.rdc.2024.03.001_bib67","first-page":"OA2973","article-title":"Subclinical ILD is frequent and progresses across different connective tissue diseases","volume":"58","author":"Hoffmann-Vold","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.rdc.2024.03.001_bib69","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.03.001_bib70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2024.03.001_bib71","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1164\/ajrccm.155.3.9116980","article-title":"Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease","volume":"155","author":"Tomioka","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib72","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1992.00400190139026","article-title":"Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration adverse drug reaction reports","volume":"152","author":"Goodwin","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib73","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1183\/09031936.02.00267402","article-title":"Sulphasalazine and lung toxicity","volume":"19","author":"Parry","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2024.03.001_bib74","first-page":"1082","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows","volume":"9","author":"Cassone","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib76","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2024.03.001_bib77","first-page":"6","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"154","author":"Mena-V\u00e1zquez","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rdc.2024.03.001_bib79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2015.12.004","article-title":"Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease","volume":"36","author":"Witt","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rdc.2024.03.001_bib80","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X24000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T07:32:19Z","timestamp":1719646339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X24000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0889857X24000279"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2024.03.001","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Connective Tissue Disease Associated Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}